In people with an autosomal-dominant AD mutation, Aβ and tau start accumulating long before the estimated onset of symptoms.
A Japanese company enters the arena with a plasma Aβ test that rivals CSF for detecting brain amyloid.
Certified reference material by which companies can calibrate assays is now available worldwide.
PET scans indicate no more AD pathology in PD-MCI than healthy controls, suggesting their cognitive decline results from other factors.
In people who carry a repeat expansion in the C9ORF72 gene, gray and white matter are smaller and subtle impairments in cognition appear decades before symptom onset.
Clinical validation is showing automated Elecsys, Lumipulse assays to be reliable and predictive. The story on blood tests has turned from non-starter to intensely promising for broad-based screening.
Tau’s apparent lockstep with cognitive decline dominated the PET conversation. Piramal flaunted data, and Merck/Cerveau are close behind. A first stab at imaging synapses in the hippocampus drew notice, too.
Alzheimer’s science has undergone a paradigm shift toward the disease’s silent phase. For trials, this means change at every level: new participants, new screening tools, new outcome measurements. What’s the progress?
Slow vital capacity, a measure of respiratory function, predicted the rate of disease progression in ALS patients, suggesting the test could be used as a primary endpoint in clinical trials.
The neurodegeneration marker appears to track disease severity in AD and MS patients with great sensitivity.
A longitudinal study identified regions in the default mode network as among the first to accumulate Aβ.
Participants in the A4 prevention trial wanted to know the extent of their amyloid burdens and how that affected their risk for AD. Researchers need to carefully communicate the limitations of amyloid PET.
Researchers debut a statistical model that uses MRI, CSF, and demographic data to compute a cognitively impaired person’s risk for progressing to dementia.
Tau in the plasma rises after traumatic brain injury, with cognitive decline, and progression to mild cognitive impairment.
In a pilot study, a curcumin-based probe allowed researchers to detect retinal amyloid deposits in AD patients, but it remains to be seen if this can serve as an early biomarker.